Dapagliflozin improves podocytes injury in diabetic nephropathy via regulating cholesterol balance through KLF5 targeting the ABCA1 signalling pathway

Dapagliflozin improves podocytes injury in diabetic nephropathy via regulating cholesterol balance through KLF5 targeting the ABCA1 signalling pathway

Abstract Diabetic nephropathy (DN), one of the more prevalent microvascular complications in patients diagnosed with diabetes mellitus, is attributed as the main cause of end-stage renal disease (ESRD). Lipotoxicity in podocytes caused by hyperglycemia has been recognised as a significant pathology...

Full description

Bibliographic Details
Main Authors: Jingshu Sun, Xinyu Zhang, Simeng Wang, Dandan Chen, Jianqiang Shu, Nannan Chong, Qinglian Wang, Ying Xu
Format: Article
Language:English
Published: BMC 2024-02-01
Series:Diabetology & Metabolic Syndrome
Subjects:
Dapagliflozin
Diabetic Nephropathy
Cholesterol
KLF-5
ABCA1
Online Access:https://doi.org/10.1186/s13098-024-01271-6

Internet

https://doi.org/10.1186/s13098-024-01271-6

Similar Items